TY - JOUR
T1 - WHO global research priorities for sexually transmitted infections
AU - Gottlieb, Sami L.
AU - Spielman, Erica
AU - Abu-Raddad, Laith
AU - Aderoba, Adeniyi Kolade
AU - Bachmann, Laura H.
AU - Blondeel, Karel
AU - Chen, Xiang Sheng
AU - Crucitti, Tania
AU - Camacho, Gabriela Garcia
AU - Godbole, Sheela
AU - de Leon, Rodolfo Gómez Ponce
AU - Gupta, Somesh
AU - Hermez, Joumana
AU - Ishikawa, Naoko
AU - Klausner, Jeffrey D.
AU - Kurbonov, Firdavs
AU - Maatouk, Ismael
AU - Mandil, Ahmed
AU - Mello, Maeve B.
AU - Miranda, Angelica Espinosa
AU - Mosha, Fausta Shakiwa
AU - Okeibunor, Joseph Chukwudi
AU - Ong, Jason J.
AU - Peters, Remco P.H.
AU - Pérez, Freddy
AU - Seguy, Nicole
AU - Seib, Kate L.
AU - Sharma, Mukta
AU - Sladden, Tim
AU - Van Der Pol, Barbara
AU - White, Peter J.
AU - Wi, Teodora
AU - Broutet, Nathalie
N1 - Publisher Copyright:
© 2024 World Health Organization
PY - 2024/9
Y1 - 2024/9
N2 - Sexually transmitted infections (STIs) are widespread worldwide and negatively affect sexual and reproductive health. Gaps in evidence and in available tools have long hindered STI programmes and policies, particularly in resource-limited settings. In 2022, WHO initiated a research prioritisation process to identify the most important STI research areas to address the global public health need. Using an adapted Child Health and Nutrition Research Initiative methodology including two global stakeholder surveys, the process identified 40 priority STI research needs. The top priorities centred on developing and implementing affordable, feasible, rapid point-of-care STI diagnostic tests and new treatments, especially for gonorrhoea, chlamydia, and syphilis; designing new multipurpose prevention technologies and vaccines for STIs; and collecting improved STI epidemiologic data on both infection and disease outcomes. The priorities also included innovative programmatic approaches, such as new STI communication and partner management strategies. An additional six research areas related to mpox (formerly known as monkeypox) reflect the need for STI-related research during disease outbreaks where sexual transmission can have a key role. These STI research priorities provide a call to action for focus, investment, and innovation to address existing roadblocks in STI prevention, control, and management to advance sexual and reproductive health and wellbeing for all.
AB - Sexually transmitted infections (STIs) are widespread worldwide and negatively affect sexual and reproductive health. Gaps in evidence and in available tools have long hindered STI programmes and policies, particularly in resource-limited settings. In 2022, WHO initiated a research prioritisation process to identify the most important STI research areas to address the global public health need. Using an adapted Child Health and Nutrition Research Initiative methodology including two global stakeholder surveys, the process identified 40 priority STI research needs. The top priorities centred on developing and implementing affordable, feasible, rapid point-of-care STI diagnostic tests and new treatments, especially for gonorrhoea, chlamydia, and syphilis; designing new multipurpose prevention technologies and vaccines for STIs; and collecting improved STI epidemiologic data on both infection and disease outcomes. The priorities also included innovative programmatic approaches, such as new STI communication and partner management strategies. An additional six research areas related to mpox (formerly known as monkeypox) reflect the need for STI-related research during disease outbreaks where sexual transmission can have a key role. These STI research priorities provide a call to action for focus, investment, and innovation to address existing roadblocks in STI prevention, control, and management to advance sexual and reproductive health and wellbeing for all.
UR - https://www.scopus.com/pages/publications/85200417530
U2 - 10.1016/S2214-109X(24)00266-3
DO - 10.1016/S2214-109X(24)00266-3
M3 - Review Article
C2 - 39043199
AN - SCOPUS:85200417530
SN - 2214-109X
VL - 12
SP - e1544-e1551
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 9
ER -